当前位置: 首页 >> 检索结果
1. Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.
作者: Jon Lampa.;Dan Nordström.;Ronald van Vollenhoven.;Merete Lund Hetland.;Espen A Haavardsholm.;Mikkel Østergaard.;Anna Rudin.;Marte S Heiberg.;Michael Nurmohamed.;Bjorn Gudbjornsson.;Kristina Lend.;Kim Hørslev-Petersen.;Tuulikki Sokka-Isler.;Gerður Gröndal.;Simon Krabbe.;Joakim Lindqvist.;Inger Gjertsson.;Daniel Glinatsi.;Meliha Kapetanovic.;Cidem Gentline.;Anna-Birgitte Aga.;Heikki Relas.;Tove Lorenzen.;Giovanni Cagnotto.;Johan Back.;Oliver Hendricks.;Bas Dijkshoorn.;Kajsa Öberg.;Maud-Kristine Ljoså.;Eli Brodin.;Hanne Merete Lindegaard.;Annika Söderbergh.;Milad Rizk.;Alf Kastbom.;Per Larsson.;Line Uhrenholt.;Søren A Just.;David J Stevens.;Trine B Laurberg.;Gunnstein Bakland.;Inge C Olsen.;Joe Sexton.;Till Uhlig.; .
来源: Lancet Rheumatol. 2026年8卷4期e285-e294页
Pain, fatigue, and impaired health-related quality of life are common manifestations of rheumatoid arthritis. The aim of this study was to compare the effects of active conventional treatment with three different biological disease-modifying antirheumatic drugs (DMARDs) on patient-reported outcomes after 48 weeks, in patients with early rheumatoid arthritis using data from the NORD-STAR trial.
2. A randomised open-label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot).
作者: Christopher P Denton.;Philip Yee.;Medha Kanitkar.;Hannah Sims.;Charlotte Clarke.;Saiam Ahmed.;Voon H Ong.;Francesco Del Galdo.;John D Pauling.;Marina E Anderson.;Muditha Samaranayaka.;Michael Hughes.;Smita Bhat.;Bridget Griffiths.;Maya H Buch.;Ariane L Herrick.;David D'Cruz.;Madelon C Vonk.;Nick Freemantle.;Hakim-Moulay Dehbi.
来源: Rheumatology (Oxford). 2026年65卷3期
Mycophenolate mofetil (MMF) is routinely used in early diffuse cutaneous systemic sclerosis (dcSSc) but not in limited cutaneous (lc)SSc. This may miss an opportunity to slow disease progression. MINIMISE-Pilot tested the feasibility of an open-label event-driven randomised trial of MMF vs no immunosuppression in lcSSc.
3. Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study.
作者: Yu Xue.;Lingyun Sun.;Ning Zhang.;Haiying Chen.;Xiaofei Shi.;Shengyun Liu.;Lin Chen.;Xinmei Ma.;Hua Wei.;Zhenyu Jiang.;Xiaomei Li.;Hongtao Fan.;Hongbin Li.;Jingyang Li.;Rui Wu.;Guixiu Shi.;Jing Zhu.;Xiaodan Kong.;Yuewu Lu.;Pan Liu.;Qianning Zheng.;Xiaoyan Bai.;Su Zhang.;Weiguo Wan.;Hejian Zou.
来源: Rheumatology (Oxford). 2026年65卷2期
Current PsA therapies, from conventional agents (e.g. MTX) to targeted biologics (e.g. TNF and IL-17 inhibitors), demonstrate distinct therapeutic profiles. Vunakizumab (SHR-1314) is a novel humanized mAb targeting IL-17A. The phase 2 trial evaluated the efficacy and safety of vunakizumab in patients with active PsA.
4. Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.
作者: Koji Suzuki.;Hideto Kameda.;Kei Ikeda.;Tomonori Ishii.;Kosaku Murakami.;Hyota Takamatsu.;Yoshiya Tanaka.;Takayuki Abe.;Tsutomu Takeuchi.;Yuko Kaneko.
来源: Rheumatology (Oxford). 2026年65卷2期
To investigate the long-term safety and efficacy of tocilizumab, an IL-6 receptor inhibitor, in patients with adult-onset Still's disease.
5. Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial.
作者: Francisco J Blanco.;Laura Galindo.;Belen Acasuso.;Vanesa Balboa-Barreiro.;Juan D Cañete.;Benjamin Fernández-Gutiérrez.;Isidoro González-Álvaro.;José Luis Pablos Álvarez.;Carmen Bejerano-Herrería.;Maite Silva-Díaz.;Ignacio Rego-Perez.;Lucia Lourido.;Cristina Ruiz-Romero.;Miren Uriarte-Ecenarro.;Rosario García-Vicuña.;Andrea Cuervo.;Julio Ramírez.;Raquel Celis.;Luis Rodríguez-Rodríguez.;Lydia Abasolo Alcázar.;Dalifer Freites Nuñez.;Maria Martín-López.;Francisco J Toro-Santos.;Natividad Oreiro.
来源: Rheumatology (Oxford). 2026年65卷3期
The aim of this study was to identify robust predictive markers which may help personalize tapering protocols, minimizing flare risk while optimizing long-term disease management in RA patients.
6. Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome.
作者: Oreola Donini.;Bercemhan Sulu.;Christopher Pullion.;Adam Rumage.;Richard Straube.;Christopher Schaber.;Gülen Hatemi.
来源: Rheumatology (Oxford). 2026年65卷2期
The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Behçet's syndrome.
7. Transcutaneous auricular vagus nerve stimulation versus sham stimulation in patients with erosive hand osteoarthritis (ESTIVAL): a randomised, multicentre, double-blind, sham-controlled trial.
作者: Alice Courties.;Sophie Tuffet.;Grégoire Cormier.;Christian H Roux.;Paul Ornetti.;Yves-Marie Pers.;Jacques-Éric Gottenberg.;Eric Lespessailles.;Roland Chapurlat.;Denis Arniaud.;François Rannou.;Daniel Wendling.;Florent Eymard.;Sylvain Mathieu.;Pascal Richette.;Alain Saraux.;Hubert Marotte.;Nicolas Poursac.;Anne-Christine Rat.;Jean-Philippe Bastard.;Soraya Fellahi.;Yves Henrotin.;Lise Minssen.;Camille Deprouw.;Christelle Nguyen.;Amel Touati.;Laurence Bérard.;Alexandra Rousseau.;Tabassome Simon.;Emmanuel Maheu.;Francis Berenbaum.;Jérémie Sellam.
来源: Lancet Rheumatol. 2026年8卷2期e98-e107页
Erosive hand osteoarthritis is a painful and inflammatory disease without effective treatments. In this study we aimed to investigate the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) compared with sham stimulation in patients with inflammatory erosive hand osteoarthritis.
8. Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies.
作者: Gonul Hazal Koc.;Marc R Kok.;Fazira R Kasiem.;Jolanda J Luime.;Ilja Tchetverikov.;Kim Wilhelm-de Jong.;Lindy A Korswagen.;Natasja H A M Denissen.;Yvonne P M Goekoop-Ruiterman.;Paul Baudoin.;Petra Kok.;Reinhard Bos.;Radboud J E M Dolhain.;Marijn Vis.
来源: Lancet Rheumatol. 2026年8卷1期e23-e32页
Treat-to-target strategies have previously been shown to improve outcomes in psoriatic arthritis. We aimed to evaluate whether a treat-to-target strategy using early intensive treatment with the IL-17A inhibitor secukinumab improves outcomes compared with a standard step-up treat-to-target approach in patients with psoriatic arthritis.
9. Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial.
作者: David J Beard.;Loretta J Davies.;Jonathan A Cook.;Graeme MacLennan.;Jemma Hudson.;Andrew J Price.;Andrew J Carr.;Matthew Little.;Jose Leal.;Ray Fitzpatrick.;David W Murray.;Marion K Campbell.; .
来源: Lancet Rheumatol. 2026年8卷2期e116-e126页
The Total or Partial Knee Arthroplasty Trial (TOPKAT) aimed to evaluate the difference between total knee replacement (TKR) and partial (unicompartmental) replacement (PKR) for treatment of late-stage medial compartment knee osteoarthritis. As longevity is a key issue for joint replacement, extended follow-up periods are required to fully evaluate the long-term efficacy. In this analysis, we report the 10-year follow-up of the TOPKAT trial.
10. Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.
作者: Ming-Hui Zhao.;Fidencio Cons Molina.;Gustavo Aroca.;Maria G Tektonidou.;Anubhav Mathur.;Radhika Tangadpalli.;Rui Sun.;Ruvie Martin.;Pascale Pellet.;Thao Ngoc Phuong Huynh.
来源: Rheumatology (Oxford). 2026年65卷1期
The objective of this study was to evaluate the efficacy and safety of s.c. secukinumab 300 mg combined with standard of care (SoC) in adult patients with active LN.
11. Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.
作者: Philip J Mease.;Laura C Coates.;Corine Gaillez.;Alexis Shew.;Weibin Bao.;Christopher T Ritchlin.
来源: Rheumatology (Oxford). 2026年65卷1期
To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with PsA receiving secukinumab.
12. Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis.
作者: Helena Marzo-Ortega.;Iain B McInnes.;Mohamed Sharaf.;Alen Zabotti.;Emmanouil Rampakakis.;Dennis McGonagle.;Ahmed Abogamal.;Pascal Richette.;Georg Schett.
来源: Rheumatology (Oxford). 2026年65卷1期
To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).
13. Efficacy and safety of a millimetre wave medical device for pain neuromodulation in peripheral OA: a crossover randomized trial.
作者: Caroline Maindet.;Joris Giai.;Corentin Leroy.;Marion Proust.;Gilliane Lalami.;Isabelle Boudry.;Marlène Thiers.;Jean-Luc Bosson.;Laurent Grange.
来源: Rheumatology (Oxford). 2026年65卷1期
To manage OA-related pain, current guidelines recommend a combination of non-pharmacological and pharmacological treatments. The objective of this study was to assess a millimetre-wave-emitting medical device (MD) for neuromodulation of pain in patients with peripheral OA.
14. Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
作者: Venkatesh Krishnan.;Stuart Y Keller.;Christine Chew.;Jonathan T Sims.;Ching-Yun Chang.;Ernst R Dow.;Robert J Benschop.;Rona Wang.;Athimalaipet V Ramanan.
来源: Lancet Rheumatol. 2025年7卷11期e799-e807页
Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
15. Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.
作者: Gabriele De Marco.;Elizabeth M A Hensor.;Philip S Helliwell.;Shabina Sultan.;Sayam R Dubash.;Xabier Michelena.;Laura C Coates.;Paul Emery.;Ai Lyn Tan.;Dennis McGonagle.;Helena Marzo-Ortega.
来源: Lancet Rheumatol. 2025年7卷11期e776-e788页
The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.
16. Effect of an intensive smoking cessation intervention on smoking cessation and disease activity in patients with RA: a randomized controlled trial.
作者: Bente Appel Esbensen.;Thordis Thomsen.;Ida Kristiane Roelsgaard.;Mikkel Østergaard.;Merete Lund Hetland.;Lena Andersen.;Hanne Tønnesen.;Anne Grete Semb.;Robin Christensen.
来源: Rheumatology (Oxford). 2026年65卷1期
To compare the effect of a 6-week individual intensive smoking cessation intervention in patients with RA, relative to treatment-as-usual, on the co-primary outcomes (1) successful smoking cessation and (2) achievement of EULAR clinical response (improvement in DAS28-CRP of >0.6) 3 months post-intervention. Secondary outcomes were number of swollen joints, tender joints, CRP, patient and physician global assessment, pain, fatigue, flare, physical function and health related quality of life.
17. Personalised gait retraining for medial compartment knee osteoarthritis: a randomised controlled trial.
作者: Scott D Uhlrich.;Valentina Mazzoli.;Amy Silder.;Andrea K Finlay.;Feliks Kogan.;Garry E Gold.;Scott L Delp.;Gary S Beaupre.;Julie A Kolesar.
来源: Lancet Rheumatol. 2025年7卷10期e708-e718页
Retraining individuals with medial compartment knee osteoarthritis to walk with a patient-specific change in their foot angle (ie, toe-in or toe-out angle) can reduce excessive joint loading related to disease progression. This study investigated the clinical, biomechanical, and structural efficacy of personalised foot progression angle modifications compared with sham treatment in patients with mild-to-moderate medial compartment knee osteoarthritis.
18. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial.
作者: Mark Hancock.;Anne Smith.;Peter O'Sullivan.;Robert Schütze.;J P Caneiro.;Robert Laird.;Kieran O'Sullivan.;Jan Hartvigsen.;Amity Campbell.;Deborah Wareham.;Ruth Chang.;Peter Kent.
来源: Lancet Rheumatol. 2025年7卷11期e789-e798页
Interventions for low back pain typically produce small and short-term effects. Cognitive functional therapy (CFT) has shown large effects up to 12 months, but long-term effects are unclear. We aimed to compare the long-term (3-year) effectiveness of CFT, delivered with or without movement sensor biofeedback, with usual care for patients with chronic disabling low back pain.
19. Clinical and cost-effectiveness of a cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial.
作者: Thomas W Wainwright.;Tikki Immins.;Sharon Docherty.;Geoff Saunders.;Annie Hawton.;Elizabeth Goodwin.;Tim Rees.;Matthew Low.;Jo Samways.;Fran Webley.;Nikki Howard.;Paul H Lee.;Robert G Middleton.
来源: Lancet Rheumatol. 2025年7卷11期e764-e775页
Osteoarthritis of the hip is a leading cause of chronic disability. The cycling and education intervention (CLEAT) trial aimed to compare the clinical and cost-effectiveness of the cycling against hip pain (CHAIN) intervention, a group-based cycling and education programme, with usual physiotherapy care for patients with hip osteoarthritis referred for physiotherapy at a UK hospital.
20. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.
作者: Jacques Morel.;Emmanuelle Dernis.;Christian Roux.;Christophe Richez.;Olivier Brocq.;Bruno Fautrel.;Carine Salliot.;Olivier Vittecoq.;Xavier Mariette.;Frederic Lioté.;Slim Lassoued.;Cécile Gaujoux-Viala.;Arnaud Constantin.;Martin Soubrier.;Valérie Devauchelle-Pensec.;Vincent Goeb.;Jacques-Eric Gottenberg.;Hubert Marotte.;Anouck Rémy Moulard.;Claire Daien.;Gael Mouterde.;Cédric Lukas.;Joana Pissarra.;Helena Huguet.;Odile Launay.;Florence Galtier.;Marie Christine Picot.; .; .
来源: Lancet Rheumatol. 2025年7卷10期e675-e686页
Pneumococcal vaccination is recommended for patients with rheumatoid arthritis. Because immunosuppressant therapies for rheumatoid arthritis hinder vaccine efficacy, vaccination should be administered before initiating immunosuppressive drugs. We aimed to compare humoral responses in patients with rheumatoid arthritis receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before methotrexate initiation or simultaneously.
|